Dave Ricks, Eli Lilly CEO (File photo/AP)
July 29, 2021 07:23 AM EDTUpdated 07:34 AM
Deals

Eli Lil­ly teams up with KRAS drug pi­o­neer Yi Liu tar­get­ing small mol­e­cule I/O with $70M up­front

Kyle Blankenship

Among the ma­jor drug­mak­ers, on­col­o­gy has be­come a gold rush in re­cent years with the big dogs hoover­ing up re­search part­ners along the way. One …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times